74 related articles for article (PubMed ID: 2202768)
1. [Study on carbohydrate antigen NCC-ST-439 in breast cancer].
Suzuki S; Nihei M; Nomizu T; Watanabe T; Kimijima I; Tsuchiya A; Abe R
Nihon Gan Chiryo Gakkai Shi; 1990 May; 25(5):1019-26. PubMed ID: 2202768
[TBL] [Abstract][Full Text] [Related]
2. [Clinical significance of a tumor marker NCC-ST-439 in breast cancer--a comparative study with CA 15-3, CEA and TPA].
Okamura Y; Takatsuka Y; Katoh T; Tsumura I; Kobayakawa K; Kawahara T
Gan To Kagaku Ryoho; 1991 Jul; 18(8):1279-85. PubMed ID: 2069399
[TBL] [Abstract][Full Text] [Related]
3. [Study on the clinical usefulness of NCC-ST-439 in breast cancer].
Takahashi H; Nakanishi K; Taguchi K; Hasumi T; Hamada H; Sasaki F; Hata Y; Uchino J
Gan To Kagaku Ryoho; 1991 Feb; 18(2):245-9. PubMed ID: 1992918
[TBL] [Abstract][Full Text] [Related]
4. A comparative analysis of the serum levels of NCC-ST-439, CEA and CA19-9 in patients with colorectal carcinoma.
Iemura K; Moriya Y
Eur J Surg Oncol; 1993 Oct; 19(5):439-42. PubMed ID: 8405479
[TBL] [Abstract][Full Text] [Related]
5. [The expression of NCC-ST-439, a tumor marker, in human breast cancer patients].
Miyahara E; Toi M; Wada T; Yamada H; Osaki A; Yanagawa E; Toge T
Gan No Rinsho; 1990 Sep; 36(11):2023-6. PubMed ID: 2232168
[TBL] [Abstract][Full Text] [Related]
6. [Clinical usefulness of tumor markers in breast cancer].
Konishi K; Karaki K; Watanabe K; Tsuda H; Konishi F
Rinsho Byori; 1993 Oct; 41(10):1108-15. PubMed ID: 8254956
[TBL] [Abstract][Full Text] [Related]
7. [Clinical significance of serum NCC-ST 439 as a tumor marker for colorectal cancer].
Yamaguchi A; Kurosaka Y; Ohta N; Kamata T; Ishida T; Nishimura G; Katoh M; Kosaka T; Yonemura Y; Miyazaki I
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2645-50. PubMed ID: 2549882
[TBL] [Abstract][Full Text] [Related]
8. [Study for clinical usefulness of CEA, TPA, CA15-3 and BCA225 in breast cancer].
Kaneko Y; Imoto S; Kasakura S
Rinsho Byori; 1995 Jul; 43(7):696-702. PubMed ID: 7674542
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of serum Her2/neu, BCL2, CA15-3 and CEA in breast cancer patients: a short follow-up.
Samy N; Ragab HM; El Maksoud NA; Shaalan M
Cancer Biomark; 2010; 6(2):63-72. PubMed ID: 20571232
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of tumor marker CA15-3 in breast cancer].
Kikuchi K; Uematsu Y; Takada Y; Kurihara E; Suito T; Fujisaki M; Takahashi R; Tamura T
Gan To Kagaku Ryoho; 1987 Nov; 14(11):3095-100. PubMed ID: 3479052
[TBL] [Abstract][Full Text] [Related]
11. [Clinical evaluation of tumor markers in breast cancer patients].
Ito T; Tanaka S; Ban K; Sakai N; Oshita H; Oiwa T; Kanno A; Kashizuka T
Gan To Kagaku Ryoho; 1987 Oct; 14(10):2917-23. PubMed ID: 3310907
[TBL] [Abstract][Full Text] [Related]
12. [CA15-3 tumor marker in early detection of breast cancer].
Roisman I; Shiloni E; Lifshiz I; Shoshani D; Saphir D; Honigman I; Livni N; Sherman Y; Papo O; Durst AL
Harefuah; 1992 Feb; 122(4):213-8. PubMed ID: 1563679
[TBL] [Abstract][Full Text] [Related]
13. [Elevation of serum Ca 15-3 antigen: an early indicator of distant metastasis from breast cancer. Retrospective analysis of 733 cases].
Wojtacki J; Kruszewski WJ; Sliwińska M; Kruszewska E; Hajdukiewicz W; Sliwiński W; Rolka-Stempniewicz G; Góralczyk M; Leśniewski-Kmak K
Przegl Lek; 2001; 58(6):498-503. PubMed ID: 11816740
[TBL] [Abstract][Full Text] [Related]
14. CA15-3 serum levels in breast cancer and other malignancies--correlation with clinical course.
Barak V; Carlin D; Sulkes A; Treves A; Biran S
Isr J Med Sci; 1988; 24(9-10):623-7. PubMed ID: 3204010
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer.
Ogawa Y; Ishikawa T; Ikeda K; Nakata B; Sawada T; Ogisawa K; Kato Y; Hirakawa K
Clin Cancer Res; 2000 Oct; 6(10):4069-72. PubMed ID: 11051258
[TBL] [Abstract][Full Text] [Related]
16. [Clinical evaluation of serum level of NCC-ST-439 as a new tumor marker for colorectal diseases--fluctuation of serum NCC-ST-439 in patients with colorectal cancers before and after surgery].
Sakurai Y; Kodaira S; Teramoto T; Sugano K; Abe O; Ohtake H; Iri H
Gan To Kagaku Ryoho; 1989 Sep; 16(9):3205-12. PubMed ID: 2782914
[TBL] [Abstract][Full Text] [Related]
17. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.
Hiramatsu K; Takahashi K; Yamaguchi T; Matsumoto H; Miyamoto H; Tanaka S; Tanaka C; Tamamori Y; Imajo M; Kawaguchi M; Toi M; Mori T; Kawakita M
Clin Cancer Res; 2005 Apr; 11(8):2986-90. PubMed ID: 15837752
[TBL] [Abstract][Full Text] [Related]
18. Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker.
Bray KR; Koda JE; Gaur PK
Cancer Res; 1987 Nov; 47(22):5853-60. PubMed ID: 2444335
[TBL] [Abstract][Full Text] [Related]
19. [Study on the clinical usefulness of NCC-ST-439 in cases of digestive tract cancer].
Anzai K; Kurihara M; Izumi T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1437-47. PubMed ID: 2212836
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of an immunoradiometric assay for CA15-3 antigen associated with human mammary carcinomas: comparison with carcinoembryonic antigen.
Fujino N; Haga Y; Sakamoto K; Egami H; Kimura M; Nishimura R; Akagi M
Jpn J Clin Oncol; 1986 Dec; 16(4):335-46. PubMed ID: 3467106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
